TIMOTHY CHARLES THOMPSON

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. Reagan A, Gu X, Hauck S, Ash J, Cao G, Thompson T, et al. Retinal Caveolin-1 Modulates Neuroprotective Signaling. Adv Exp Med Biol. 2016;854:411-8 pubmed publisher
    ..Thus, Cav-1 modulates neuroprotective signaling by regulating the endogenous production of neuroprotective factors. ..
  2. Karanika S, Karantanos T, Kurosaka S, Wang J, Hirayama T, Yang G, et al. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. Mol Cancer. 2015;14:122 pubmed publisher
  3. Thompson T. Glioma pathogenesis-related protein 1: tumor-suppressor activities and therapeutic potential. Yonsei Med J. 2010;51:479-83 pubmed publisher
    ..In conclusion, restoration of GLIPR1 function in prostate cancer cells through GLIPR1 gene-based or GLIPR protein-based delivery methods may provide a safe and effective approach for targeted therapy for a range of malignancies. ..
  4. Thompson T, Tahir S, Li L, Watanabe M, Naruishi K, Yang G, et al. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis. 2010;13:6-11 pubmed publisher
    ..Secreted cav-1 is therefore a potential biomarker and therapeutic target for prostate cancer. ..
  5. Fujita T, Satoh T, Timme T, Hirayama T, Zhu J, Kusaka N, et al. Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models. Urol Oncol. 2014;32:92-100 pubmed publisher
    ..Combining AdGlipr1 (AdGLIPR1) with radiotherapy may achieve additive or synergistic tumor control in selected prostate and bladder tumors, and additional therapeutic effects may result with repeated treatment cycles. ..
  6. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, et al. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal. 2014;7:ra47 pubmed publisher
    ..Our results reveal new mechanism-based therapeutic approaches for PCa by targeting PARP and the DDR pathway involving c-Myb, TopBP1, ataxia telangiectasia mutated- and Rad3-related (ATR), and Chk1. ..
  7. Karanika S, Karantanos T, Li L, Wang J, Park S, Yang G, et al. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Rep. 2017;18:1970-1981 pubmed publisher
    ..These findings have important clinical implications, since they introduce a therapeutic strategy for AR-positive, metastatic, castration-resistant PCa, regardless of p53 status, through targeting AR-CDC6-ATR-Chk1 signaling. ..
  8. Li L, Karanika S, Yang G, Wang J, Park S, Broom B, et al. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017;10: pubmed publisher
    ..Thus, antiandrogen and PARP inhibitor combination therapy may be effective for CRPC patients and suggests that pharmaceutically inducing BRCAness may expand the clinical use of PARP inhibitors. ..
  9. Zhang W, Liu B, Wu W, Li L, Broom B, Basourakos S, et al. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res. 2018;24:696-707 pubmed publisher
    ..i>Clin Cancer Res; 24(3); 696-707. ©2017 AACR. ..